Clavulanic acid/amoxicillin (1 : 14)(CVA/AMPC 〈1 : 14〉) was administered for 5 days to 642 children with acute rhinosinusitis complicated by acute pharyngitis, judged to be severe according to the “Guidelines on the Diagnosis and Treatment of Acute Rhinosinusitis”, to investigate the efficacy of this drug combination. The response rate was 67%. An analysis of the clinical efficacy in terms of patient age revealed that the response rate was significantly higher for children age 3 years or older (73%) than in children under age 3 (57%). A bacteriological investigation isolated 1050 strains of bacteria from the mucopurulent nasal discharge, with
S.pneumoniae (286 strains, 27%) and
H.influenzae (501 strains, 48%) together accounting for 75%. The MIC
90 of CVA/AMPC (1 : 14) was 1 μg/ml for
S.pneumoniae and 16 μg/ml for
H.influenzae, and the response rate for this drug combination was significantly higher for
S.pneumoniae detected independently than for
H.influenzae detected independently. The adverse drug reaction of diarrhea occurred in 34% of patients. There were cases with penicillin-resistant
S. pneumoniae (PRSP) that did not respond to CVA/AMPC (1 : 14), and their courses therefore need to be monitored carefully while paying close attention to any changes in the drug susceptibility of
S.pneumoniae, including PRSP.
View full abstract